DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)

127.43 1.97 (1.57%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALNY $127.43 1.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $126.55
Previous Close $125.46
Daily Range $124.82 - $130.00
52-Week Range $52.35 - $140.00
Market Cap $10.7B
P/E Ratio -70.88
Dividend (Yield) $0.00 (0.0%)
Volume 414,275
Average Daily Volume 749,661
Current FY EPS -$2.96

Sector

Healthcare

Industry

Drug Makers

Alnylam Pharmaceuticals (ALNY) Description

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes. Website: http://www.alnylam.com/

News & Commentary

How Rare-Disease Drugmaker Alexion Pharmaceuticals Found Its Groove in June

A trio of positive events sends rare disease-drug developer Alexion shooting higher by a double-digit percentage. Can the good times continue?

3 Stocks Pushing The Drugs Industry Downward

First Week of March 2016 Options Trading For Alnylam Pharmaceuticals (ALNY)

An Assessment Of Celgene's Deal For Receptos

Health Care Sector Update for 07/20/2015: HRTX, ALNY, STEM

Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therape

Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)

Today's Stocks Driving Success For The Drugs Industry

Use Options For a Chance To Buy ALNY at a 37% Discount

Benitec And Bluebird Bio, Gene Therapy Coming Of Age?

5 Biotech Stocks On Deck With The FDA

See More ALNY News...

ALNY's Top Competitors

ALNY $127.43 (1.57%)
Current stock: ALNY
AMGN $176.59 (2.85%)
Current stock: AMGN
GILD $117.86 (-0.03%)
Current stock: GILD
BIIB $318.78 (0.56%)
Current stock: BIIB